Pfizer Inc

PFE-N

NYSE:PFE

40.51
0.10 (0.25%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
BUY
BUY
March 13, 2018

Likes healthcare. Boasts a 3.7% yield that'll likely increase, decent cash flow and growth. Company could spin-off.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
March 13, 2018

Likes healthcare. Boasts a 3.7% yield that'll likely increase, decent cash flow and growth. Company could spin-off.

COMMENT
COMMENT
March 8, 2018

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
March 8, 2018

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).

COMMENT
COMMENT
February 14, 2018

Likes healthcare, but he has a tough time with drug companies. It takes a long time to get a patent with lots of research. Pfzier, though, has legacy, long-term drugs to draw on. This is an income vehicle. Doesn't expect new products right now. An income, not a growth play.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 14, 2018

Likes healthcare, but he has a tough time with drug companies. It takes a long time to get a patent with lots of research. Pfzier, though, has legacy, long-term drugs to draw on. This is an income vehicle. Doesn't expect new products right now. An income, not a growth play.

DON'T BUY
DON'T BUY
January 29, 2018

You could ask if there is a better way to hold it so that you get a currency hedge. ZUH-T does this to give you healthcare sector exposure. He would wait until the dollar moves back to 77 cents. If the Canadian dollar was higher than 80 cents you would not want hedged exposure.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 29, 2018

You could ask if there is a better way to hold it so that you get a currency hedge. ZUH-T does this to give you healthcare sector exposure. He would wait until the dollar moves back to 77 cents. If the Canadian dollar was higher than 80 cents you would not want hedged exposure.

HOLD
HOLD
January 29, 2018

If you exclude the impact of the Hosperian Fusion System divestiture, revenues for the quarter increased 4%. They've done OK, but thank God for tax cuts, because on a dividend standard, they've had 9% five-year growth, but the average for 10 years has been 1%.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 29, 2018

If you exclude the impact of the Hosperian Fusion System divestiture, revenues for the quarter increased 4%. They've done OK, but thank God for tax cuts, because on a dividend standard, they've had 9% five-year growth, but the average for 10 years has been 1%.

DON'T BUY
DON'T BUY
January 19, 2018

He would not be a buyer. The company has a fairly well-defined top, about $2 higher than what it is right now. Also doesn't have a lot of FMV potential. The stock has been struggling to get higher and it hasn't been dynamic. Thinks that when it hits technical resistance and FMV resistance at the same time, it's toast. If you own, you could hold it for another $1, but that would be it.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 19, 2018

He would not be a buyer. The company has a fairly well-defined top, about $2 higher than what it is right now. Also doesn't have a lot of FMV potential. The stock has been struggling to get higher and it hasn't been dynamic. Thinks that when it hits technical resistance and FMV resistance at the same time, it's toast. If you own, you could hold it for another $1, but that would be it.

TOP PICK
TOP PICK
January 10, 2018

Has a lot of money parked offshore, which they can now repatriate and do M&A with. They need M&A because they have a lacklustre pipeline of drugs. The stock has been dead money for 5 years. Trading at 13.5X PE, and the market trades at about 19X PE Forward. Very cheap. They’re growing the dividend and are buying back stock. EPS should go up, because of stock buybacks. Thinks the stock will be going up 15% because of all the tailwinds. Dividend yield of 3.7%. (Analysts' price target is $39.)

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 10, 2018

Has a lot of money parked offshore, which they can now repatriate and do M&A with. They need M&A because they have a lacklustre pipeline of drugs. The stock has been dead money for 5 years. Trading at 13.5X PE, and the market trades at about 19X PE Forward. Very cheap. They’re growing the dividend and are buying back stock. EPS should go up, because of stock buybacks. Thinks the stock will be going up 15% because of all the tailwinds. Dividend yield of 3.7%. (Analysts' price target is $39.)

HOLD
HOLD
November 30, 2017

Nothing outstanding is going to happen to the company. Their pipeline is encouraging them. Continue to collect your 3.5% dividend and watch for a catalyst.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 30, 2017

Nothing outstanding is going to happen to the company. Their pipeline is encouraging them. Continue to collect your 3.5% dividend and watch for a catalyst.

Don Lato

Unlock Ratings

Price
$36.260
Owned
Unknown
COMMENT
COMMENT
November 28, 2017

With everybody aging, pharmaceuticals should be a place to be. However, they’re all struggling, coming up with new drugs, which are getting more and more expensive to do the R&D for. Cash flow is hurting all of them. They are facing a very tough regulatory environment. The only way this company has been able to grow is to make acquisitions. He struggles with the whole sector.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 28, 2017

With everybody aging, pharmaceuticals should be a place to be. However, they’re all struggling, coming up with new drugs, which are getting more and more expensive to do the R&D for. Cash flow is hurting all of them. They are facing a very tough regulatory environment. The only way this company has been able to grow is to make acquisitions. He struggles with the whole sector.

PAST TOP PICK
PAST TOP PICK
November 22, 2017

(A Top Pick Dec 28/16. Up 14%.) This has given him decent earnings along the way and they have raised the dividend along the way. A good company and a good story to keep. They are investigating whether they are going to split the company in 2.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 22, 2017

(A Top Pick Dec 28/16. Up 14%.) This has given him decent earnings along the way and they have raised the dividend along the way. A good company and a good story to keep. They are investigating whether they are going to split the company in 2.

BUY
BUY
November 13, 2017

One of the great American pharmaceutical stocks. A little cheaper than a lot of them. They don’t have a whole series of blockbusters hitting the lights out, but have a very diverse product line. They’ve made some acquisitions and will make more. Extremely well-managed. Believes it can drift towards the low $40. A good solid Buy and Hold. Dividend yield of 3.6%.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 13, 2017

One of the great American pharmaceutical stocks. A little cheaper than a lot of them. They don’t have a whole series of blockbusters hitting the lights out, but have a very diverse product line. They’ve made some acquisitions and will make more. Extremely well-managed. Believes it can drift towards the low $40. A good solid Buy and Hold. Dividend yield of 3.6%.

BUY
BUY
October 26, 2017

A Pharma US stock with dividends and growth. PFE-T is the one he would recommend. It is a very well run company with a steady dividend and a good pipeline of new drugs. It has pretty good shareholder friendly management that buy back stock and create value. It is his favourite way to participate in aging demographics.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 26, 2017

A Pharma US stock with dividends and growth. PFE-T is the one he would recommend. It is a very well run company with a steady dividend and a good pipeline of new drugs. It has pretty good shareholder friendly management that buy back stock and create value. It is his favourite way to participate in aging demographics.

COMMENT
COMMENT
October 23, 2017

In the 90s, drug companies traded at 30X earnings with 10% earnings growth. All the drug companies are suffering badly because they are not getting a good return on R&D. Every country is putting pressure on pharmaceutical prices. This is trading at 20X earnings and has lots of free cash flow, but the drug sector is simply a very difficult place to be.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 23, 2017

In the 90s, drug companies traded at 30X earnings with 10% earnings growth. All the drug companies are suffering badly because they are not getting a good return on R&D. Every country is putting pressure on pharmaceutical prices. This is trading at 20X earnings and has lots of free cash flow, but the drug sector is simply a very difficult place to be.

COMMENT
COMMENT
October 17, 2017

Has owned this for a long time. Rates of return over the last 5 or 6 years have been mediocre. Trading at $36, and his model price is $45.72, a 27% upside. Pays a 3.56% dividend. They have been totally incompetent. If rates of return ever kept up with the rest of the drug space, he would buy it here and hold it, but it is a frustrating stock.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 17, 2017

Has owned this for a long time. Rates of return over the last 5 or 6 years have been mediocre. Trading at $36, and his model price is $45.72, a 27% upside. Pays a 3.56% dividend. They have been totally incompetent. If rates of return ever kept up with the rest of the drug space, he would buy it here and hold it, but it is a frustrating stock.

COMMENT
COMMENT
September 22, 2017

The trouble with these kind of drug companies is that they made lots of acquisitions, which is how they have grown. Many were considered growth companies because they came out with social drugs, and ended up with huge multiples. There are lots of good things in their pipeline, but there are not going to be these massive, massive blockbuster drugs they used to have.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 22, 2017

The trouble with these kind of drug companies is that they made lots of acquisitions, which is how they have grown. Many were considered growth companies because they came out with social drugs, and ended up with huge multiples. There are lots of good things in their pipeline, but there are not going to be these massive, massive blockbuster drugs they used to have.

Showing 46 to 60 of 670 entries